Welcome to our dedicated page for Durect news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on Durect stock.
DURECT Corporation (Nasdaq: DRRX) is a specialized biopharmaceutical company focused on the research, development, and manufacturing of innovative pharmaceutical products. With expertise in drug discovery, delivery, and development, DURECT dedicates its efforts to creating therapies aimed at pain management, acute organ injury, and metabolic diseases. Their proprietary technologies, including oral, transdermal, and injectable depot delivery systems, enhance clinical and commercial attributes such as abuse deterrence, convenience, adherence, efficacy, and safety for both small molecule and biologic drugs.
One of DURECT’s key assets is larsucosterol, an epigenetic modulator currently in Phase 3 clinical trials for the treatment of severe alcohol-associated hepatitis (AH). This promising candidate has received both Fast Track and Breakthrough Therapy designations from the FDA. The company's Phase 2b AHFIRM trial demonstrated significant potential in reducing mortality among AH patients, paving the way for further research and development.
Another noteworthy product is POSIMIR®, an FDA-approved non-opioid analgesic for post-surgical pain management, which utilizes DURECT’s SABER® platform technology. It is exclusively licensed to Innocoll Pharmaceuticals for distribution in the United States.
DURECT also markets ALZET® osmotic pumps, widely used in preclinical research for continuous drug delivery in laboratory animals. A collaboration with Charles River Laboratories aims to further expand the reach of this product line within the pharmaceutical and academic sectors.
Financially, DURECT continues to advance its pipeline with strategic capital management, ensuring the sustainability of its operations while actively seeking regulatory approvals for its drug candidates. Their latest developments include quarterly financial reports, conference calls with stakeholders, and presentations at major medical conferences, showcasing their commitment to transparency and progress.
For more information, visit www.durect.com and follow the company on X (formerly Twitter) at https://x.com/DURECTCorp.
DURECT (Nasdaq: DRRX) will report its first quarter 2024 financial results on May 13, 2024. The company focuses on epigenetic therapies for severe conditions like organ injury and cancer. A conference call and webcast will follow to discuss the results and provide a corporate update.
DURECT (Nasdaq: DRRX) announced a late-breaking oral presentation at the EASL Congress 2024 to discuss data from the Phase 2b AHFIRM trial on larsucosterol for severe alcohol-associated hepatitis. The presentation will be held on June 8, 2024, in Milan, Italy.
FAQ
What is the current stock price of Durect (DRRX)?
What is the market cap of Durect (DRRX)?
What is DURECT Corporation's primary focus?
What are DURECT's key products?
What is larsucosterol?
Has larsucosterol received any special designations from the FDA?
What is POSIMIR®?
Who distributes POSIMIR® in the United States?
What are ALZET® osmotic pumps?
What recent financial updates has DURECT provided?
How does DURECT engage with the scientific community?
Where can I find more information about DURECT Corporation?
